Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance

Journal of Medicinal Chemistry

Volumn 60, Issue 10, 2017, Pages 4185-4211

  Lasalle, Manuel ^a,b   Hoguet, Vanessa ^a,b   Hennuyer, Nathalie ^b   Leroux, Florence ^b   Piveteau, Catherine ^b   Belloy, Loïc ^b   Lestavel, Sophie ^b   Vallez, Emmanuelle ^b   Dorchies, Emilie ^b   Duplan, Isabelle ^b   Sevin, Emmanuel ^c   Culot, Maxime ^c   Gosselet, Fabien ^c   Boulahjar, Rajaa ^b   Herledan, Adrien ^b   Staels, Bart ^b   Deprez, Benoit ^b   Tailleux, Anne ^a,b   Charton, Julie ^a,b  

^a U1177 Drugs and Molecules for Living Systems ^*

^b UNIV LILLE   (France)

^c UNIVERSITÉ D'ARTOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(3,4 DIMETHOXY PHENYL) METHYL AMINE; (3,4 DIMETHOXY PHENYL) [2 (2 FLUORO BENZYLSULFANYL) 3 (4 FLUOROPHENYL) 3H IMIDAZOL 4 YL] METHYL AMINE; (3,4 DIMETHOXY PHENYL) [2 (2,6 DIMETHYL BENZYLSULFANYL) 3 (4 FLUORO PHENYL) 3H IMIDAZOL 4 YL] METHYL AMINE; 2 CHLORO N (3,4 DIMETHOXY PHENYL) N METHYL ACETAMIDE; 2 [2 (2,6 DIFLUORO BENZYL) 3 PHENYL ISOTHIOUREIDO] N (3,4 DIMETHOXY PHENYL) N METHYL ACETAMIDE; 2 [2 (2,6 DIFLUORO-BENZYL) 3 (4 FLUORO PHENYL) ISOTHIOUREIDO] N (3,4 DIMETHOXY PHENYL) N METHYL ACETAMIDE; 2 [2 BENZYL 3 (4 FLUORO PHENYL) ISOTHIOUREIDO] N (3,4 DIMETHOXYPHENYL) N METHYL ACETAMIDE; 3 [4 [[5 (3,4 DIMETHOXY N METHYL ANILINO) 1 (4 FLUOROPHENYL) IMIDAZOL 2 YL]SULFANYLMETHYL] 3,5 DIFLUORO PHENOXY]PROPANE 1 SULFONATE AMMONIUM; 5 (2,6 DIFLUORO BENZYLSULFANYL) 4 (4 FLUORO PHENYL) 4H [1,2,4] TRIAZOL 3 YLAMINE; 5 (2,6 DIFLUORO BENZYLSULFANYL) 4 (4 FLUORO PHENYL) 4H [1,2,4] TRIAZOL 3 YL] (3,4 DIMETHOXY PHENYL) METHYL AMINE; 5 AMINO 4 (4 FLUORO PHENYL) 4H [1,2,4]TRIAZOLE 3 THIOL; ANTIDIABETIC AGENT; G PROTEIN COUPLED BILE ACID RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; IMIDAZOLE DERIVATIVE; N (3,4 DIMETHOXY PHENYL) 2 [2 (2 FLUORO BENZYL) 3 (4 FLUOROPHENYL) ISOTHIOUREIDO] N METHYL ACETAMIDE; N (3,4 DIMETHOXY PHENYL) 2 [2 (2,6 DIMETHYL BENZYL) 3 (4 FLUORO PHENYL) ISOTHIOUREIDO] N METHYL ACETAMIDE; N (3,4 DIMETHOXY PHENYL) 2 [3 (4 FLUORO PHENYL) ISOTHIOUREIDO] N METHYL ACETAMIDE; N (3,4 DIMETHOXY PHENYL) N METHYL 2 (3 PHENYL ISOTHIOUREIDO) ACETAMIDE; N [5 (2,6 DIFLUORO BENZYLSULFANYL) 4 (4 FLUORO PHENYL) 4H [1,2,4] TRIAZOL 3 YL] ACETAMIDE; N [5 (2,6 DIFLUORO BENZYLSULFANYL) 4 (4 FLUORO PHENYL) 4H [1,2,4] TRIAZOL 3 YL] N (3,4 DIMETHOXY PHENYL) ACETAMIDE; SITAGLIPTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; [2 (2,6 DIFLUORO BENZYLSULFANYL) 3 (4 FLUORO PHENYL) 3H IMIDAZOL 4 YL] (3,4 DIMETHOXY PHENYL) METHYL AMINE; [2 (3,4 DIMETHOXY N METHYL ANILINO) 2 OXO ETHYL]AMMONIUM FORMATE; [2 BENZYLSULFANYL 3 (4 FLUORO PHENYL) 3H IMIDAZOL 4 YL] (3,4 DIMETHOXY PHENYL) METHYL AMINE; [3 [4 [5 [(3,4 DIMETHOXY PHENYL) METHYLAMINO] 1 (4 FLUORO PHENYL) 1H IMIDAZOL 2 YLSULFANYLMETHYL] 3,5 DIFLUORO PHENYL] PROP 2 YNYL] TRIMETHYLAMMONIUM FORMATE; [5 (2,6 DIFLUORO BENZYLSULFANYL) 4 (4 FLUORO PHENYL) 4H [1,2,4] TRIAZOL 3 YL] (3,4 DIMETHOXY PHENYL) AMINE; [5 (2,6 DIFLUORO BENZYLSULFANYL) 4 (4 FLUORO PHENYL) 4H [1,2,4] TRIAZOL 3 YL] METHYL AMINE; GLUCOSE; GPBAR1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACO-2 CELL LINE; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; GALLBLADDER MOTILITY; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN RESISTANCE; INTESTINE ABSORPTION; INTRINSIC CLEARANCE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MICROWAVE IRRADIATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOPHILICITY; ORAL GLUCOSE TOLERANCE TEST; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; SONOGASHIRA REACTION; STRUCTURE ACTIVITY RELATION; SURFACE AREA; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; AGONISTS; AMINATION; ANIMAL; C57BL MOUSE; CHEMISTRY; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; INTESTINE; METABOLISM;

AMINATION; ANIMALS; CACO-2 CELLS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INTESTINAL ABSORPTION; INTESTINES; MICE, INBRED C57BL; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85019758042     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01873     Document Type: Article

References (30)

1. Lefebvre, P.; Cariou, B.; Lien, F.; Kuipers, F.; Staels, B. Role of bile acids and bile acid receptors in metabolic regulation Physiol. Rev. 2009, 89, 147-191 10.1152/physrev.00010.2008
2. Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR Mol. Cell 1999, 3, 543-553 10.1016/S1097-2765(00)80348-2
3. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Nakamura, T.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR) Biochem. Biophys. Res. Commun. 2002, 298, 714-719 10.1016/S0006-291X(02)02550-0
4. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; Hinuma, S.; Fujisawa, Y.; Fujino, M. A G protein-coupled receptor responsive to bile acids J. Biol. Chem. 2003, 278, 9435-9440 10.1074/jbc.M209706200
5. Porez, G.; Prawitt, J.; Gross, B.; Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease J. Lipid Res. 2012, 53, 1723-1737 10.1194/jlr.R024794
6. Campbell, J. E.; Drucker, D. J. Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab. 2013, 17, 819-837 10.1016/j.cmet.2013.04.008
7. Watanabe, M.; Houten, S. M.; Mataki, C.; Christoffolete, M. A.; Kim, B. W.; Sato, H.; Messaddeq, N.; Harney, J. W.; Ezaki, O.; Kodama, T.; Schoonjans, K.; Bianco, A. C.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation Nature 2006, 439, 484-489 10.1038/nature04330
8. Broeders, E. P.; Nascimento, E. B.; Havekes, B.; Brans, B.; Roumans, K. H.; Tailleux, A.; Schaart, G.; Kouach, M.; Charton, J.; Deprez, B.; Bouvy, N. D.; Mottaghy, F.; Staels, B.; van Marken Lichtenbelt, W. D.; Schrauwen, P. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity Cell Metab. 2015, 22, 418-426 10.1016/j.cmet.2015.07.002
9. Lavoie, B.; Balemba, O. B.; Godfrey, C.; Watson, C. A.; Vassileva, G.; Corvera, C. U.; Nelson, M. T.; Mawe, G. M. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels J. Physiol. 2010, 588, 3295-3305 10.1113/jphysiol.2010.192146
10. Keitel, V.; Cupisti, K.; Ullmer, C.; Knoefel, W. T.; Kubitz, R.; Häussinger, D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders Hepatology 2009, 50, 861-870 10.1002/hep.23032
11. Alemi, F.; Kwon, E.; Poole, D. P.; Lieu, T.; Lyo, V.; Cattaruzza, F.; Cevikbas, F.; Steinhoff, M.; Nassini, R.; Materazzi, S.; Guerrero-Alba, R.; Valdez-Morales, E.; Cottrell, G. S.; Schoonjans, K.; Geppetti, P.; Vanner, S. J.; Bunnett, N. W.; Corvera, C. U. The TGR5 receptor mediates bile acid-induced itch and analgesia J. Clin. Invest. 2013, 123, 1513-1530 10.1172/JCI64551
12. Futatsugi, K.; Bahnck, K. B.; Brenner, M. B.; Buxton, J.; Chin, J. E.; Coffey, S. B.; Dubins, J.; Flynn, D.; Gautreau, D.; Guzman-Perez, A.; Hadcock, J. R.; Hepworth, D.; Herr, M.; Hinchey, T.; Janssen, A. M.; Jennings, S. M.; Jiao, W.; Lavergne, S. Y.; Li, B.; Li, M.; Munchhof, M. J.; Orr, S. T. M.; Piotrowski, D. W.; Roush, N. S.; Sammons, M.; Stevens, B. D.; Storer, G.; Wang, J.; Warmus, J. S.; Wei, L.; Wolford, A. C. Optimization of triazole-based TGR5 agonists towards orally available agents MedChemComm 2013, 4, 205-210 10.1039/C2MD20174G
13. Piotrowski, D. W.; Futatsugi, K.; Warmus, J. S.; Orr, S. T.; Freeman-Cook, K. D.; Londregan, A. T.; Wei, L.; Jennings, S. M.; Herr, M.; Coffey, S. B.; Jiao, W.; Storer, G.; Hepworth, D.; Wang, J.; Lavergne, S. Y.; Chin, J. E.; Hadcock, J. R.; Brenner, M. B.; Wolford, A. C.; Janssen, A. M.; Roush, N. S.; Buxton, J.; Hinchey, T.; Kalgutkar, A. S.; Sharma, R.; Flynn, D. A. Identification of tetrahydropyrido[4,3-d]pyrimidine amides as a new class of orally bioavailable TGR5 agonists ACS Med. Chem. Lett. 2013, 4, 63-68 10.1021/ml300277t
14. Ca)-dependent mechanism J. Pharmacol. Exp. Ther. 2014, 348, 421-431 10.1124/jpet.113.210005
15. Charmot, D. Non-systemic drugs: a critical review Curr. Pharm. Des. 2012, 18, 1434-1445 10.2174/138161212799504858
16. Duan, H.; Ning, M.; Zou, Q.; Ye, Y.; Feng, Y.; Zhang, L.; Leng, Y.; Shen, J. Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes J. Med. Chem. 2015, 58, 3315-3328 10.1021/jm500829b
17. Cao, H.; Chen, Z.-X.; Wang, K.; Ning, M.-M.; Zou, Q.-A.; Feng, Y.; Ye, Y.-L.; Leng, Y.; Shen, J.-H. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect Sci. Rep. 2016, 6, 28676 10.1038/srep28676
18. Kramer, W.; Glombik, H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs Curr. Med. Chem. 2006, 13, 997-1016 10.2174/092986706776361003
19. Bollu, V.; Boren, B. C.; Dalgard, J. E.; Flatt, B. T.; HAQ, N.; Hudson, S.; Mohan, R.; Morrissey, M.; Pratt, B.; Wang, T.-L. Triazole and Imidazole Derivatives for Use as TGR5 Agonists in the Treatment of Diabetes and Obesity. World Patent WO2010/093845, 2010.
20. Zamansky, I.; Galvin, G.; Girardet, J.-L. Polymorphic, Crystalline and Mesophase Forms of Sodium 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate, and Uses Thereof. World Patent WO/2011/085009, 2011.
21. Lasalle, M.; Picon, S.; Rajaa, B.; Hoguet, V.; Van Obbergen, J.; Roussel, P.; Deprez, B.; Charton, J. Access to newly functionalized imidazole derivatives: efficient synthesis of novel 5-amino-2-thioimidazoles using propylphosphonic anhydride (®T3P) Tetrahedron Lett. 2015, 56, 1011-1014 10.1016/j.tetlet.2015.01.046
22. Fournie-Zaluski, M.-C.; Llorens-Cortes, C.; Roques, B. P.; Corvol, P. Novel derivatives of 4,4′-dithiobis-(3-aminobutane-1-sulfphonates) and compositions containing same. US 2006/0135602, 2006.
23. Egan, W. J.; Merz, K. M.; Baldwin, J. J. Prediction of drug absorption using multivariate statistics J. Med. Chem. 2000, 43, 3867-3877 10.1021/jm000292e
24. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 2002, 45, 2615-2623 10.1021/jm020017n
25. Palm, K.; Stenberg, P.; Luthman, K.; Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans Pharm. Res. 1997, 14, 568-571 10.1023/A:1012188625088
26. Li, T.; Holmstrom, S. R.; Kir, S.; Umetani, M.; Schmidt, D. R.; Kliewer, S. A.; Mangelsdorf, D. J. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling Mol. Endocrinol. 2011, 25, 1066-1071 10.1210/me.2010-0460
27. Briere, D. A.; Ruan, X.; Cheng, C. C.; Siesky, A. M.; Fitch, T. E.; Dominguez, C.; Gutierrez Sanfeliciano, S.; Montero, C.; Suen, C. S.; Xu, Y.; Coskun, T.; Michael, M. D. Novel small molecule agonist of TGR5 possesses anti-diabetic effects but causes gallbladder filling in mice PLoS One 2015, 10, e0136873 10.1371/journal.pone.0136873
28. Brighton, C. A.; Rievaj, J.; Kuhre, R. E.; Glass, L. L.; Schoonjans, K.; Holst, J. J.; Gribble, F. M.; Reimann, F. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors Endocrinology 2015, 156, 3961-3970 10.1210/en.2015-1321
29. Charton, J.; Deprez, B.; Leroux, F.; Staels, B.; Muhr-Tailleux, A.; Hennuyer, N.; Lestavel, S.; Lasalle, M.; Dubanchet, B. Imidazol-or 1,2,4-Triazol-Derivatives and Their Use. World Patent WO2015/189330 A1, 2015.
30. Sevin, E.; Dehouck, L.; Fabulas-da Costa, A.; Cecchelli, R.; Dehouck, M. P.; Lundquist, S.; Culot, M. Accelerated Caco-2 cell permeability model for drug discovery J. Pharmacol. Toxicol. Methods 2013, 68, 334-339 10.1016/j.vascn.2013.07.004